共 50 条
- [41] ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer[J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (04):Ghoshdastidar, KrishnarupPatel, HoshangBhayani, HiteshPatel, AnkitThakkar, KinjalPatel, DineshSharma, ManoranjanSingh, JaideepMohapatra, JogeswarChatterjee, AbhijitPatel, DipamBahekar, RajeshSharma, RajivGupta, LakshmikantPatel, NirmalGiri, PoonamSrinivas, Nuggehally R.Jain, MukulBandyopadhyay, DebduttaPatel, Pankaj R.Desai, Ranjit C.
- [42] Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective Inhibition to the BTK/HCK Dual Inhibition - Delving into the Inhibitory Activity of KIN-8194 against BTK, and HCK in the Treatment of Mutated BTKCys481 Waldenström Macroglobulinemia: A Computational Approach[J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2024, 24 (11) : 813 - 825Elamin, GhaziAljoundi, AimenAlahmdi, Mohamed I.Abo-Dya, Nader E.Soliman, Mahmoud E. S.
- [43] The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity[J]. BIOLOGICAL CHEMISTRY, 2004, 385 (05) : 409 - 413van den Akker, Evan Dijk, TBSchmidt, UFelida, LBeug, HLöwenberg, Bvon Lindern, M
- [44] Discovery and optimization of a novel series of highly selective Btk inhibitors with application in autoimmune and inflammatory disease[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241Currie, Kevin S.
- [45] Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK)[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (03) : 632 - 635Lou, YanLopez, FranciscoJiang, YongyingHan, XiaochunBrotherton, ChrisBilledeau, RolandGabriel, SteveGleason, ShellyGoldstein, David M.Hilgenkamp, RamonaKocer, BuelentOrzechowski, LucjaTan, JennyWovkulich, PeterWen, BoFry, DavidDi Lello, PaolaChen, LucyZhang, Fang-jieFretland, JenniferNangia, AnjaliYang, TianOwens, Timothy D.
- [46] Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (02) : 145 - 151Kawahata, WataruAsami, TokikoIrie, TakayukiSawa, Masaaki
- [47] LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin[J]. ALLERGY, 2019, 74 : 332 - 332Kaul, M.Storim, J.End, P.Cabanski, M.Jakab, A.Schuhler, C.Funhoff, E.Schaefer, F.Dimanova, E.Kistowska, M.Kinhikar, A.Maiolica, A.Sinn, A.Fuhr, R.Cenni, B.
- [48] Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies[J]. BLOOD, 2011, 118 (21) : 1487 - 1487Evans, EricaTester, RichlandAslanian, SharonChaturvedi, PrasoonMazdiyasni, HormozPonader, SabineTesar, BethanySheets, MichaelNacht, MarianaStiede, KathrynWitowski, SteveLounsbury, HeatherPetter, RussellBrown, Jennifer R.Burger, Jan A.Singh, JuswinderWestlin, William F.
- [49] Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 246Fang, XiaobaoLiu, ChunxiaoZhang, KunYang, WanpingWu, ZewenShen, ShigeMa, YuleLu, XunChen, YadongLu, TaoHu, QinghuaJiang, Yulei
- [50] GB5121 is a novel highly potent and selective CNS-penetrant BTK inhibitor for CNS malignancies[J]. CANCER RESEARCH, 2022, 82 (12)Yusuf, IsharatSahdeo, SunilIsmaili, TaylorNaiman, ZacharyGuimond, DavidSchiff, TheodoreClemons, BryanHerman, KrystalPaulson, BryannaHou, KayMeadows, Kristen TaylorKennedy, MichaelRose, MarkCarter, Laura